These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

531 related items for PubMed ID: 19243708

  • 21. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [Abstract] [Full Text] [Related]

  • 22. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [Abstract] [Full Text] [Related]

  • 23. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.
    Cerebrovasc Dis; 2013 Oct; 36(2):145-51. PubMed ID: 24029780
    [Abstract] [Full Text] [Related]

  • 24. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes.
    Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M, Exubera Phase 3 Study Group.
    Int J Clin Pract; 2007 Oct; 61(10):1614-25. PubMed ID: 17877648
    [Abstract] [Full Text] [Related]

  • 25. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes.
    Sambanis C, Tziomalos K, Kountana E, Kakavas N, Zografou I, Balaska A, Koulas G, Karagiannis A, Zamboulis C.
    Acta Diabetol; 2008 Mar; 45(1):23-30. PubMed ID: 17768592
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 27. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
    Ruaño G, Bernene J, Windemuth A, Bower B, Wencker D, Seip RL, Kocherla M, Holford TR, Petit WA, Hanks S.
    Clin Chim Acta; 2009 Feb; 400(1-2):48-55. PubMed ID: 18996102
    [Abstract] [Full Text] [Related]

  • 28. Thiazolidinediones and the risk of edema: a meta-analysis.
    Berlie HD, Kalus JS, Jaber LA.
    Diabetes Res Clin Pract; 2007 May; 76(2):279-89. PubMed ID: 17055103
    [Abstract] [Full Text] [Related]

  • 29. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.
    Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP.
    J Am Coll Cardiol; 2007 Apr 24; 49(16):1696-704. PubMed ID: 17448371
    [Abstract] [Full Text] [Related]

  • 30. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association.
    Circulation; 2003 Dec 09; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract] [Full Text] [Related]

  • 31. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 09; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 32. Massive bilateral pleural effusion associated with use of pioglitazone.
    Chen YW, Chen YC, Wu CJ, Chen HH.
    Clin Ther; 2008 Aug 09; 30(8):1485-9. PubMed ID: 18803990
    [Abstract] [Full Text] [Related]

  • 33. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
    Abbasi F, Lima NK, Reaven GM.
    Metabolism; 2009 Mar 09; 58(3):373-8. PubMed ID: 19217454
    [Abstract] [Full Text] [Related]

  • 34. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC.
    J Pharm Pharmacol; 2008 Dec 09; 60(12):1573-82. PubMed ID: 19000361
    [Abstract] [Full Text] [Related]

  • 35. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE, Hanna A.
    Diabetes Obes Metab; 2008 Apr 09; 10(4):312-28. PubMed ID: 18333890
    [Abstract] [Full Text] [Related]

  • 36. Thiazolidinediones and heart failure: a teleo-analysis.
    Singh S, Loke YK, Furberg CD.
    Diabetes Care; 2007 Aug 09; 30(8):2148-53. PubMed ID: 17536074
    [Abstract] [Full Text] [Related]

  • 37. Pioglitazone for diabetes prevention in impaired glucose tolerance.
    DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD, ACT NOW Study.
    N Engl J Med; 2011 Mar 24; 364(12):1104-15. PubMed ID: 21428766
    [Abstract] [Full Text] [Related]

  • 38. Pioglitazone induced reversible pancytopenia.
    Karakurt F, Kargili A, Kasapoglu B.
    Exp Clin Endocrinol Diabetes; 2010 Feb 24; 118(2):96-7. PubMed ID: 19834871
    [Abstract] [Full Text] [Related]

  • 39. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
    Shargorodsky M, Michaelova K, Boaz M, Gavish D, Zimlichman R.
    Diabet Med; 2007 Nov 24; 24(11):1254-60. PubMed ID: 17725634
    [Abstract] [Full Text] [Related]

  • 40. Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
    Vudhironarit T, Benjasuratwong Y, Patarakitvanit S, Temboonkiat S, Satyapan N.
    J Med Assoc Thai; 2009 Feb 24; 92 Suppl 1():S124-8. PubMed ID: 21299185
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.